10月25日cbcs乳腺腫瘤研究院winer-krop邵對(duì)話提綱

1、邵教授 3 人提綱開(kāi)場(chǎng)白：的管理進(jìn)入到了分子分型時(shí)代，針對(duì)不同分子分型的患者建立起不同類型的治療方案。但治療方案絕不是一成不變的，需要根據(jù)患者的具體情況來(lái)對(duì)方案做出細(xì)調(diào)，這也就邵教授、Winer 教授和是所說(shuō)的化治療。今天很榮幸邀請(qǐng)到三位的化治療。Krop 教授 一起來(lái)談一談 HER-2 陽(yáng)性患者的The management of breast cancer has enteredo an era of Molecular clasffication . Various therapyregimens have been established for patients with corre

2、sponding molecular subtype. But the regimen isnot inflexible, fine-tuning is nesary given the specific patient. Itst what we called italized treatment. Today, We are grey honored by inviting three prestigious figures in breast cancer field, Professor Shao,Professor Winer,and Professor Krop , to disc

3、uss a few key topics inalized treatment of HER-2itive patients.1.的化治療可以體現(xiàn)在哪些方面？（外/在中）治療領(lǐng)域比如早期的治療，of all, Professor Shao ,Professor Winer and Professor Krop,reatment of breast cancer, alized treatment in Chinasuch as ear and US?r stage cancer, what respects are they reflected for2.今年年初正式于的 APT 研究提示，對(duì)

4、于特定患者，單用曲妥珠單抗和紫杉醇單藥輔助治療即可達(dá)到很好的生存結(jié)局，這應(yīng)該就是化治療的一個(gè)非常好的例子。Winer 教授和 Kan 教授都參與了 APT 試驗(yàn)，請(qǐng)二位分別評(píng)價(jià)一下這個(gè)研究？（2 外）Earrhis year, the APT trial published in NEJM demonstratedt, for specific patients whouse singly either Trastuzumab or paaxel as adjuvant therapy，can have favorable survivale. This should berfect exle

5、 ofalized treatment. Professor Winer and Krophave all participated in APT, so, please give us your commments/share your thoughts on this trial.3.，早期抗 HER-2 治療的化是如何開(kāi)展的，有無(wú)輔助或新輔助化治療的例子或臨床試驗(yàn)？（中）Professor Shao, in China, how to providealized treatment for patients with earr stagebreast cancer, and are th

6、ere some cases or trials involved in adjuvant and neoadjuvant therapy?4.無(wú)論是輔助治療還是新輔助治療，總是希望有一些敏感性好的、特異性高的分子標(biāo)志經(jīng)驗(yàn)嗎？（美+中；物來(lái)幫助中必須）判斷患者的治療應(yīng)答或預(yù)后。在這一方面三位教授In adjuvant and neoadjuvant therapy, no matter what type it is, we all wisht we have somehighly sensitive and specific molecular biomarks to predict the

7、 treatment response or prognosis.So, Professor Winer and Professor Krop，what would be your comments on it? ?And Professor Shao, whats your opinions?5.ALTTO 研究告訴，曲妥珠單抗聯(lián)合替尼并不優(yōu)于單用曲妥珠單抗，您如何其他雙聯(lián)組合，如曲妥珠單抗聯(lián)合珠單抗的前景？此外，目前新輔助治療的應(yīng)用人群越來(lái)越廣，適應(yīng)疾病分期也越來(lái)越早，雙靶向治療在 HER-2 陽(yáng)性何前景？（外）新輔助治療領(lǐng)域有The ALTTO trial has shownt Tras

8、tuzumab combined with Lapatinib, not bettern useTrastuzumab singly. So, Professor Winer and Professor Krop，how do you view the future ofdouble combination, such asbined with Lapatinib?Furthermore, neoadjuvant therapy have been usedore and more patients, and are suited toear (r and earr cancer stage.

9、 So, what are the prospects of double bined with Lapatinib)in neoadjuvant therapy for HER-2ingitive breast cancerpatients？6.對(duì)于 HER-2 陽(yáng)性的轉(zhuǎn)移性中），您目前慣常選擇哪種一線治療和二線治療方案？（外+Currently, for HER-2itive metasic breast cancer,which regimen is commonly used inline and second line treatment scenario/strategy? ?7.

10、T-DM1 在已經(jīng)上市，Winer 教授和 Krop 教授剛才也都提到了它在 HER2 +轉(zhuǎn)移性乳腺癌二線或以上治療中的應(yīng)用（注意前一個(gè)問(wèn)題的回答，根據(jù)實(shí)際情況對(duì)這一部分進(jìn)行措辭）。能否請(qǐng)二位教授談一談這個(gè)藥物的價(jià)值和應(yīng)用前景？它的安全性怎樣？（外）T-DM1 has been launched in US, Professor Winer and Krop have mentioned its application inHER-2itive metasic breast cancer in second line treatment and above. So, please explai

11、nmore or elaborate its clinical value and indication prospect.And how about its safety profiles?8.中國(guó)還沒(méi)有T-DM1，您如何的應(yīng)用前景?（中）它未來(lái)In China, T-DM1is not available yet, So, Professor Shao，how do you consider its future clinial use prospectin China?9.最后轉(zhuǎn)換一下話題。真實(shí)世界研究和臨床試驗(yàn)互為補(bǔ)充，二者都是不可替代的。請(qǐng)幾位教授向講解一下真實(shí)世界數(shù)據(jù)的作用和意義？

12、（外+中）Now, lets move to the next topic. Real World Research and evidence from clinical trial cancomplement each other, and bore non-replaceable. So, please give us a general description ofthe function and significance of real-world data.10.真實(shí)世界的數(shù)據(jù)從何而來(lái)？在相關(guān)數(shù)據(jù)庫(kù)的建設(shè)方面，外+中）和中國(guó)的現(xiàn)狀各自如何？（1Where is the data of real-world d cur